STOCK TITAN
  1. Home
  2. News
  3. GCTK

GlucoTrack, Inc. - GCTK STOCK NEWS

Welcome to our dedicated page for GlucoTrack news (Ticker: GCTK), a resource for investors and traders seeking the latest updates and insights on GlucoTrack stock.

GlucoTrack, Inc. (symbol: GCTK) is a pioneering medical device company focused on the innovation and commercialization of non-invasive glucose monitoring devices. Established in 2001, the company aims to improve the quality of life for individuals with diabetes by eliminating the pain and inconvenience associated with traditional glucose monitoring methods. Since its inception, GlucoTrack has been dedicated to developing breakthrough technologies that provide a seamless glucose monitoring experience.

The company’s flagship product, the GlucoTrack® model DF-F, utilizes a unique combination of ultrasound, thermal, and electromagnetic technologies along with a proprietary algorithm to measure glucose levels without the need for painful finger pricks. This device has received CE Mark approval in June 2013 and KFDA approval in March 2016. Currently, the GlucoTrack® model DF-F is marketed across the European Union and South Korea.

In November 2011, GlucoTrack went public, further broadening its scope and capabilities in the medical device industry. The company has completed a successful feasibility study indicating that the non-invasive sensor design has a minimum two-year implant life. An ongoing animal study with an initial prototype system has also shown promising results, demonstrating a straightforward implant procedure and effective functionality.

GlucoTrack, Inc. continues to focus on enhancing its product offerings and expanding its market presence through strategic partnerships and continuous innovation. For the latest updates and information about GlucoTrack, visit the company’s official website or contact their investor relations team at: investors@glucotrack.com.

News

GLUCOTRACK EXPANDS LEADERSHIP TEAM WITH NEW VICE PRESIDENT OF QUALITY

Rhea-AI Summary
Glucotrack, Inc. (Nasdaq: GCTK) announced the appointment of Vincent Wong as Vice President of Quality. Wong brings extensive experience in life sciences and medical device manufacturing, focusing on Quality Management functions and FDA inspections. His role will involve overseeing Quality System implementation and ISO-13485 certification for the Company's Continuous Blood Glucose Monitoring technology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
management
-
News

GLUCOTRACK SELECTS CIRTEC MEDICAL AS MANUFACTURER FOR ITS IMPLANTABLE CONTINUOUS BLOOD GLUCOSE MONITOR

Rhea-AI Summary
Glucotrack, Inc. (Nasdaq: GCTK) partners with Cirtec Medical Corp for manufacturing of implantable Continuous Blood Glucose Monitor, a long-term system with 2+ years sensor longevity. The companies signed a development agreement for clinical and commercial manufacturing, aiming to accelerate human clinical trials and commercialization.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.73%
Tags
none
-
News

GLUCOTRACK ANNOUNCES THE APPOINTMENT OF LUIS MALAVÉ TO CHAIR OF THE BOARD OF DIRECTORS

Rhea-AI Summary
Glucotrack, Inc. (Nasdaq: GCTK) appoints Luis Malavé as Chairman of its Board of Directors, bringing over 30 years of leadership experience in the MedTech industry, particularly in diabetes management. His expertise in product development, operations, marketing, and strategic partnerships will drive the company's growth. Malavé's background includes roles at EOFLOW CO. Ltd., Palyon Medical, Insulet Corp., and MiniMed, showcasing a strong track record in the medical technology sector.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.87%
Tags
management
News

GLUCOTRACK ANNOUNCES EARLY ACCURACY DATA FOR ITS IMPLANTABLE CONTINUOUS GLUCOSE MONITOR

Rhea-AI Summary
GlucoTrack, Inc. (Nasdaq: GCTK) announces successful completion of initial preclinical testing for the implantable Continuous Blood Glucose Monitor™ (CBGM), demonstrating a Mean Absolute Relative Difference (MARD) of 8.1% at Day 30 and 4.5% at Day 60. CEO Paul Goode expresses confidence in the device's safety and accuracy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.78%
Tags
none
-
News

GLUCOTRACK ANNOUNCES 180-DAY EXTENSION TO REGAIN COMPLIANCE WITH NASDAQ MINIMUM BID PRICE REQUIREMENT

Rhea-AI Summary
Glucotrack, Inc. (Nasdaq: GCTK) has been granted an additional 180-day compliance period by Nasdaq to regain compliance with the minimum bid price rule, extending until May 20, 2024. The Company received the notification letter from Nasdaq after its common stock no longer met the minimum $1.00 bid price per share requirement. Glucotrack is required to maintain a closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days to regain compliance with Nasdaq's rule.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
23.4%
Tags
none
-
News

GLUCOTRACK ANNOUNCES SHAREHOLDER UPDATE

Rhea-AI Summary
Glucotrack, Inc. (Nasdaq: GCTK) Announces Strategic Shift Towards Continuous Glucose Monitoring Technology
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.62%
Tags
none
News

GLUCOTRACK ANNOUNCES PRECLINICAL TESTING WITH IMPLANTABLE CONTINUOUS GLUCOSE MONITOR

Rhea-AI Summary
Glucotrack announces milestone in development of implantable glucose monitor
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-20.65%
Tags
none
-
News

GLUCOTRACK ANNOUNCES THE APPOINTMENT OF ERIN CARTER TO BOARD OF DIRECTORS

Rhea-AI Summary
Glucotrack appoints Erin Carter as Chair of its Audit Committee, bringing 30 years of executive level finance experience in the medical device industry. Carter grew Medtronic's Gastrointestinal Solutions division from $36M to $450M in 5 years through organic growth and acquisitions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.7%
Tags
management
-
News

GLUCOTRACK ANNOUNCES NEW VP OF MARKETING

Rhea-AI Summary
Glucotrack appoints Drinda Benjamin as Vice President of Marketing
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
News

The Power Play by The Market Herald Releases New Interviews with GlucoTrack and Acceleware Discussing Their Latest News

Rhea-AI Summary
The Power Play by The Market Herald has released new interviews with GlucoTrack and Acceleware, discussing their latest news.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.04%
Tags
none

FAQ

What is the current stock price of GlucoTrack (GCTK)?

The current stock price of GlucoTrack (GCTK) is $0.258 as of December 24, 2024.

What is the market cap of GlucoTrack (GCTK)?

The market cap of GlucoTrack (GCTK) is approximately 3.7M.

What is GlucoTrack, Inc.?

GlucoTrack, Inc. is a medical device company specializing in non-invasive glucose monitoring devices for people with diabetes and pre-diabetics.

What products does GlucoTrack, Inc. offer?

GlucoTrack, Inc. offers the GlucoTrack® model DF-F, a non-invasive glucose monitor that uses ultrasound, thermal, and electromagnetic technologies along with a proprietary algorithm.

Where is the GlucoTrack® model DF-F available?

The GlucoTrack® model DF-F is currently marketed in the European Union and South Korea.

When did GlucoTrack, Inc. go public?

GlucoTrack, Inc. went public in November 2011.

What are the latest achievements of GlucoTrack, Inc.?

GlucoTrack, Inc. has completed a feasibility study and initiated an animal study demonstrating a successful sensor implant procedure and functionality.

How does GlucoTrack® model DF-F work?

The device measures glucose levels using a combination of ultrasound, thermal, and electromagnetic technologies, providing a non-invasive alternative to traditional finger stick methods.

What approvals has the GlucoTrack® model DF-F received?

The device has received CE Mark approval in June 2013 and KFDA approval in March 2016.

How can I get more information about GlucoTrack, Inc.?

You can visit the company’s official website or contact their investor relations team at investors@glucotrack.com.

What is the focus of GlucoTrack, Inc.?

GlucoTrack, Inc. focuses on improving the quality of life for people with diabetes by developing non-invasive glucose monitoring devices.

Where can I find the latest updates about GlucoTrack, Inc.?

The latest updates about GlucoTrack, Inc. can be found on the company’s official website or through their investor relations contact.

Stock GCTK logo
GlucoTrack, Inc.

Nasdaq:GCTK

GCTK Rankings

N/A Ranked by Market Cap
N/A Ranked by Dividends

GCTK Stock Data

3.74M
11.18M
34.98%
0.95%
0.66%
Medical Instruments & Supplies
Surgical & Medical Instruments & Apparatus
Link
United States of America
RUTHERFORD